Pharmaceutical & medical
Home diagnostics delivery a catalyst for medical moulding growth
and medical equipment, drug delivery components and surgical equipment. Rising demand for medical devices across hospitals and laboratories during the COVID-19 pandemic has had a positive impact on market growth. In order to safely deliver healthcare during the pandemic, telehealth and outpatient care spiked with virtual healthcare models reshaping attitudes and acceptance towards ‘at home tests’. Within Sumitomo (SHI) Demag, demand for medical technology solutions rose by almost 50 per cent during the pandemic. Here, the focus was on delivering machines to support the production of applications for IVDs to support the devices which perform COVID-19 tests. The main products being pipette tips and PCR-plates.
P
The global medical injection moulding market size was valued at $1.38 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 8.2 per cent between 2020 and 2027. Much of this growth is being driven by advances in the home healthcare sector and an aging population, which WHO predicts will double by 2050. Here, managing director of Sumitomo (SHI) Demag UK Nigel Flowers examines the transformational technologies that will play a role in future treatment pathways and how UK moulders are fostering cooperation and expanding their medical device moulding capabilities. With approximately 70 per cent of UK
lastic moulding continues to be used for many medical applications, including manufacturing implantable components, test tubes, beakers, casings and housings for laboratory
clinical decisions based on IVD tests, over 900 million tests performed every year and a predicted 10 per cent annual increase in demand for blood and tissue tests in the next 10 years, the UK’s advanced and dynamic IVD market has huge export potential notes national association BIVDA. “Rising costs and demographic shifts, most
notably driven by higher life expectancies, inevitably places even greater pressure on already stretched healthcare services,” observes Nigel Flowers. Britain’s over 65s already outnumber under 16s. By 2030, around 20 per cent of people in England will be over 65. “This rising age demographic presents serious challenges with regard to managing chronic diseases. But as we have observed during the pandemic and the shift towards virtual appointments, larger scale adoption of home healthcare programmes and smart diagnostic devices is no longer regarded as untenable.”
THe pARADIGM SHIFT Often referred to as the Internet of Medical Things (IoMT), the evolution of remote monitoring solutions to efficiently treat patients combined with significant R&D in medical monitoring and diagnostic applications is already causing a paradigm shift in the MedTech space. Estimated to be worth $56.5 million by 2027, for moulders already producing vital monitoring devices, e.g. oxygen, weight, glucose and ECG devices, as well as infusion pumps and cannulas etc. and already meeting the exacting healthcare standards, the transition to homecare device production should be relatively seamless. To enhance patient safety, there has already
been a drive towards using new and more innovative regulated materials with a better flow and high impact strength to mould components. Advanced batch tracking, contact- free inspection using cameras, and highly automated assembly are among the latest developments to meet the market’s precision and quality control requirements. As a high liability market, traceability is not just
about mandatory information and supply chain tracking. Real-time traceability is about being able to call up data and verify the exact settings used on the injection
26
January 2022 Instrumentation Monthly
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74
